Mirum Pharma appoints Rob Myers M.D. as CMO

Mirum Pharmaceuticals names a new Chief Medical Officer and outlines expected severance and equity treatment for the departing CMO.

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. (MIRM) reports a leadership transition in its medical organization. The board appointed Rob Myers, M.D. to succeed Joanne Quan, M.D. as Chief Medical Officer, effective when Dr. Myers begins employment, which is expected on September 21, 2026. Dr. Quan ceased serving as Chief Medical Officer on September 2, 2026, and her employment termination is expected on October 19, 2026, the defined “Separation Date.”

Mirum expects to enter into a Separation Agreement with Dr. Quan providing severance benefits under its Amended and Restated Severance Benefit Plan, subject to its terms. The compensation committee also approved a 12‑month post‑termination option exercise window for Dr. Quan’s vested options and payment of her 2026 annual target bonus at 100% achievement on the Separation Date, contingent on customary conditions.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Effective date CMO role ceased: September 2, 2026 Expected Separation Date: October 19, 2026 Expected start date of new CMO: September 21, 2026 +2 more

5 metrics

Effective date CMO role ceased September 2, 2026 Dr. Quan ceased serving as Chief Medical Officer on this date

Expected Separation Date October 19, 2026 Expected termination of Dr. Quan’s employment, defined as the Separation Date

Expected start date of new CMO September 21, 2026 Date Dr. Myers is expected to begin employment and become Chief Medical Officer

Post-termination option exercise period 12 months Extension for all vested and outstanding stock options held by Dr. Quan after the Separation Date

2026 annual target bonus level 100% achievement Bonus for Dr. Quan to be paid on the Separation Date, if conditions are met

Key Terms

Separation Date, Amended and Restated Severance Benefit Plan, involuntary termination, forward-looking statements, +1 more

5 terms

Separation Date financial

"the actual date of Dr. Quan’s termination of employment, the “Separation Date”"

Amended and Restated Severance Benefit Plan financial

"the severance benefits set forth in the Company’s Amended and Restated Severance Benefit Plan"

involuntary termination financial

"Dr. Quan’s separation from the Company is expected to qualify as an involuntary termination"

forward-looking statements regulatory

"contains “forward-looking statements” within the meaning of Section 27A of the Securities Act"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Separation Agreement financial

"the Company and Dr. Quan expect to enter into an agreement (the “Separation Agreement”)"

A separation agreement is a written contract that spells out the financial and legal terms when an employee and a company part ways, such as final pay, severance, continued benefits, confidentiality, and any release of claims. For investors, it matters because these agreements determine immediate costs, potential future liabilities, and whether departing staff are restricted from competing or disclosing information—factors that can affect a company’s cash flow, risk profile, and leadership continuity.

FAQ

What executive leadership change did Mirum Pharmaceuticals (MIRM) announce?

Mirum announced that its board appointed Rob Myers, M.D. to succeed Joanne Quan, M.D. as Chief Medical Officer. Dr. Myers is expected to begin employment, and thus assume the CMO role, on September 21, 2026.

When will Joanne Quan, M.D., fully separate from Mirum Pharmaceuticals (MIRM)?

Dr. Quan ceased serving as Chief Medical Officer on September 2, 2026, and her termination of employment is expected to occur on October 19, 2026, which Mirum defines as the “Separation Date.”

What severance benefits is Mirum Pharmaceuticals (MIRM) expecting to provide to Dr. Quan?

Mirum expects Dr. Quan to receive severance benefits under its Amended and Restated Severance Benefit Plan, subject to that plan’s terms, pursuant to a Separation Agreement the parties expect to enter into.

How are Dr. Quan’s stock options treated in Mirum Pharmaceuticals’ (MIRM) announcement?

The compensation committee approved extending the post‑termination exercise period for all vested and outstanding Mirum stock options held by Dr. Quan to a period expiring 12 months after the Separation Date.

What 2026 bonus payment is Mirum Pharmaceuticals (MIRM) expecting to make to Dr. Quan?

Mirum’s compensation committee approved payment, on the Separation Date, of Dr. Quan’s 2026 annual target bonus at the 100% achievement level, contingent on customary conditions in the final Separation Agreement.

Will Joanne Quan’s departure from Mirum Pharmaceuticals (MIRM) qualify as an involuntary termination?

Mirum states that Dr. Quan’s separation from the company is expected to qualify as an involuntary termination under its Amended and Restated Severance Benefit Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 08:35 AM Accepted by SEC EDGAR 09/08/2026 - 08:34 AM Learn about SEC filing dates

false000175942500017594252026-09-022026-09-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

____________________________________________________

FORM 8-K

____________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 2, 2026

____________________________________________________

Mirum Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

____________________________________________________

Delaware			001-38981			83-1281555
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
989 East Hillsdale Boulevard Suite 300
Foster City, California						94404
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 667-4085

N/A

(Former Name or Former Address, if Changed Since Last Report)

____________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share

MIRM

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 8, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced that, on September 2, 2026, the Company’s Board of Directors appointed Rob Myers, M.D., to succeed Joanne Quan, M.D., as the Company’s Chief Medical Officer, effective upon Dr. Myers’ beginning employment with the Company, which employment is expected to begin on September 21, 2026. Dr. Quan ceased to serve as the Company’s Chief Medical Officer effective September 2, 2026, and her termination of employment with the Company is expected to occur on October 19, 2026 (the actual date of Dr. Quan’s termination of employment, the “Separation Date”).

In connection with Dr. Quan’s separation from the Company, the Company and Dr. Quan expect to enter into an agreement (the “Separation Agreement”), pursuant to which, in recognition of Dr. Quan’s service to the Company, the Company expects Dr. Quan to be entitled to the severance benefits set forth in the Company’s Amended and Restated Severance Benefit Plan as then in effect (the “Severance Plan”), subject to the terms and conditions set forth in the Severance Plan. In addition, on September 2, 2026, the Compensation Committee of the Company’s Board of Directors approved (i) an extension of the post-termination exercise period for all vested and outstanding stock options granted by the Company and held by Dr. Quan on the Separation Date to a period expiring 12 months after the Separation Date and (ii) payment on the Separation Date of Dr. Quan’s 2026 annual target bonus at the 100% achievement level. Receipt of the additional benefits described in the prior sentence are contingent upon Dr. Quan satisfying certain customary conditions to be set forth in the final Separation Agreement. Dr. Quan’s separation from the Company is expected to qualify as an involuntary termination under the Severance Plan.

The foregoing description of the Separation Agreement is only a summary of the terms thereof, does not purport to be complete and is subject to, and qualified in its entirety by, the complete text of the final Separation Agreement, which the Company anticipates filing with its Quarterly Report on Form 10-Q for the three months ending September 30, 2026 or its Annual Report on Form 10-K for the year ending December 31, 2026, subject to the effective date of the Separation Agreement.

Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Generally, the words “anticipate,” “approximately,” “contingent,” “expect,” “will,” and similar expressions or their negative, may, but are not necessary to, identify forward-looking statements. Such forward-looking statements include, but are not limited to, those regarding the anticipated occurrence and timing of Dr. Quan’s separation from the Company, expected entry by the Company and Dr. Quan into the Separation Agreement and the final terms thereof, the severance benefits the Company expects Dr. Quan to receive, and the anticipated occurrence and timing of Dr. Myers beginning employment with the Company and becoming the Company’s Chief Medical Officer. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with the Company’s, Dr. Quan’s and Dr. Meyers’ future plans; and the risks and uncertainties associated with the Company’s business in general. Other factors that might cause such a difference include those discussed in the Company’s filings with the U.S. Securities and Exchange Commission, which include its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. All forward-looking statements made herein are based on information currently available to the Company as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Mirum Pharmaceuticals, Inc.
Date: September 8, 2026			By:			/s/ Christopher Peetz
						Christopher Peetz
						Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB